ClinicalTrials.gg
CompletedNCT02605837Updated Feb 19, 2025Results posted

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

A Phase 3 interventional study of Oral Budesonide Suspension (OBS) and Placebo in Eosinophilic Esophagitis (EoE), sponsored by Shire. Completed at 77 sites in United States. Open to participants aged 11 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
11 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
Largest of 18
318 · median 79
Started
2015
with 2 others
Phase 3
6 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
5 of 18
Shire

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one has the largest enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 12th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 11 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.

03

Conditions studied

  • Eosinophilic Esophagitis (EoE)
04

Who can participate

Ages eligible
11 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants is able to provide written (participant, parent or legal guardian, and, as appropriate, participant assent) to participate in the study before completing any study-related procedures.
  • Participant is male or female aged 11-55 years, inclusive, at time of consent.
  • Participant has histologic evidence of eosinophilic esophagitis (EoE) with a peak eosinophil count of greater than or equal to (>=) 15/ high-powered field (HPF), from 2 of 3 (proximal, mid-, and/or distal) levels of the esophagus at the screening endoscopy.
  • Participant has a history of clinical symptoms of esophageal dysfunction (for example, eating problems, abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) intermittently or continuously at screening (Visit -1).
  • Participants must have experienced dysphagia (response of "yes" to question 2 on Dysphagia Symptom Questionnaire [DSQ]) on a minimum of 4 days and completed the DSQ on >= 70 percent (%) of days in any 2 consecutive weeks of the screening period and in the last 2 weeks prior to the baseline visit (Visit 1).
  • Participant must not have PPI-responsive EoE based on esophageal performed after the patient has been on at least 8 weeks of high-dose PPI therapy (high-dose therapy refers to the total daily dose, which may have been administered as a once or twice daily dosing regimen). This may occur at the time of the qualifying esophagogastroduodenoscopy (EGD) (in which case the same proton pump inhibitor (PPI) regimen must be continued), or this may have been done previously (in which case PPI therapy may have been stopped if there was no response to therapy based on esophageal biopsy results). If PPI responsiveness was excluded by a previous EGD and biopsy, the historical EGD and biopsy must have been performed after the patient had been on a minimum of 6 weeks of high-dose PPI therapy.
  • Participant will be on a stable (no changes) diet >=3 months prior to the screening visit (Visit -1).
  • Participant is willing and able to continue any dietary therapy, environmental therapy, and/or medical regimens (including gastric acid suppression) in effect at the screening visit (Visit -1). There should be no change to these regimens during study participation.
  • All female participants must have a negative serum pregnancy test (beta-human chorionic gonadotropin [β-hCG]) prior to enrollment into the study. Females of must agree to continue acceptable measures (for example, abstinence, stable oral contraceptives, or double-barrier methods) throughout study participation.
  • Participant is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol.

Exclusion criteria

Exclusion Criteria

  • Participant has any condition or abnormality (including laboratory abnormalities), current or past, that, in the opinion of the principal investigator or medical monitor, would compromise the safety of the participant or interfere with or complicate the assessment of signs or symptoms of EoE. Such conditions may include psychiatric problems; neurologic deficits or disease; developmental delay; cardiovascular, metabolic, or pulmonary disease; or previous gastroesophageal surgery. These should be discussed with the medical monitor.
  • Participant has used immunomodulatory therapy within 8 weeks prior to the qualifying EGD or between the qualifying EGD and baseline visit (Visit 1) or anticipates using immunomodulatory therapy during the treatment period (except for any ongoing regimen of allergy shots). Use of long-acting immunomodulatory therapy (for example, Rituxan) within 3 months of the qualifying EGD should be reviewed with the medical monitor.
  • Participant has been using swallowed topical for EoE or systemic corticosteroid for any condition within the 4 weeks prior to the qualifying EGD, between the qualifying EGD and baseline visit (Visit 1), or anticipates use during the treatment period; any temporary use (less than or equal to [\<=]7 days) or initiation of new steroid treatment during the study should be documented and discussed with the medical monitor prospectively but cannot occur within 4 weeks of the final EGD.
  • Participant has been on inhaled steroids and has not been on stable treatment for >=3 months prior to screening visit (Visit -1). Participants on inhaled steroids need to stay on a stable treatment during study participation. Participant has been on intranasal steroids and has not been on stable treatment for a minimum of 4 weeks prior to the qualifying EGD. After the qualifying EGD, participants with seasonal allergic rhinitis may resume (or discontinue) intranasal corticosteroids based on the participant's usual treatment regimen for allergy season.
  • Participant has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, antacids, or leukotriene inhibitors for any condition (such as gastroesophageal reflux disease, asthma or allergic rhinitis) within the 4 weeks prior to the qualifying EGD, between the qualifying EGD and baseline visit (Visit 1), or anticipates changes in the use of such medications during the treatment period.
  • Participant has been using cytochrome P450 3A4 (CYP450 3A4) inhibitors (for example, ketoconazole, grapefruit juice) within the 2 weeks prior to the baseline visit (Visit 1) or within 5 half-lives (whichever is greater) or anticipates using such medications during the treatment period.
  • Participant has an appearance on qualifying EGD of an esophageal stricture (high-grade), as defined by the presence of a lesion that does not allow passage of a diagnostic adult upper endoscope (for example, with an insertion tube diameter of greater than [>]9 millimeter [mm]).
  • Participant is on a pure liquid diet or the 6-food elimination diet.
  • Participant has had an esophageal dilation within the 3 months prior to screening (Visit -1).
  • Participant has presence of esophageal varices at the screening endoscopy.
  • Participant has any current disease of the gastrointestinal tract, aside from EoE, including eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory bowel disease; or celiac disease.
  • Participant has other diseases causing or associated with EoE, including hypereosinophilic syndrome, collagen vascular disease, vasculitis, achalasia, or parasitic infection.
  • Participant has current evidence of oropharyngeal or esophageal candidiasis.
  • Participant has a potentially serious acute or chronic viral infection or immunodeficiency condition, including tuberculosis, fungal, bacterial, viral/parasite infection, ocular herpes simplex, herpes esophagitis, or chicken pox/measles.
  • Participant has upper gastrointestinal bleeding within 4 weeks prior to the screening visit (Visit - 1) or between the screening visit and baseline visit (Visit 1).
  • Participant has evidence of active infection with Helicobacter pylori.
  • Participant has evidence of unstable asthma within 4 weeks prior to the screening visit (Visit -1) and between the screening visit and baseline visit (Visit 1).
  • Participant is female and pregnant or nursing.
  • Participant has a history of intolerance, , or idiosyncratic reaction to budesonide (or any other corticosteroids) or to any other ingredients of the product.
  • Participant has taken part and received intervention in an interventional study related to EoE (except for an interventional study for a topical swallowed steroid) within 6 months prior to the screening visit (Visit -1), or any investigational study within 30 days prior to the screening visit (Visit -1). An investigational topical swallowed steroid must have been discontinued at least 30 days prior to the screening visit (Visit -1).
  • Participant has a history or high risk of noncompliance with treatment or regular clinic visits.
  • Participant has previously completed, discontinued, or withdrawn from this study.
  • Participant has participated in a previous clinical study involving oral budesonide suspension (OBS) (SHP621).
  • Participant anticipates using sucralfate during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Oral Budesonide Suspension (OBS)

    Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.

    Drug: Oral Budesonide Suspension (OBS)

  • Placebo comparator
    Placebo

    Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.

    Drug: Placebo

Interventions

  • Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.

  • DrugPlacebo

    Oral dose of 10 ml of placebo matched with the experimental drug.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16)

    Histologic response was defined as a peak eosinophil count of less than or equal to (\<=) 6/ high-powered field (HPF) across all available esophageal levels at final treatment period evaluation (Week 16). Histologic response after 12 weeks of double blind treatment at Week 16 was reported.

    Time frame: Week 16

  2. Number of Participants With Dysphagia Symptom Response at the Final Treatment Period Evaluation (Week 16)

    Dysphagia symptom response was defined as greater than or equal to (\>=) 30 percent (%) reduction in the Dysphagia Symptom Questionnaire (DSQ) combined score (questions 2+3). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Dysphagia symptom response after 12 weeks of double blind treatment at Week 16 was reported.

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16)

    DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ combined score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2 and 0 - 4 for question 3, with higher values representing a worse outcome. Scale range for DSQ combined score was 0 - 84, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ after 12 weeks of double blind treatment at Week 16 was reported.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16)

    Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 categories: 1) exudates or plaques (grade 0-2); 2) fixed esophageal rings (grade 0-3); 3) edema (grade 0-2); 4) furrows (grade 0-2); and 5) strictures (grade 0-1). An endoscopy score for each category was calculated and summed for each anatomic location (proximal and distal). The minimum and maximum endoscopy score was 0 and 10 points respectively for each location (proximal and distal) and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points respectively). The higher score indicated worse appearance. A negative change from baseline indicates that appearance improved. Endoscopic findings after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Baseline, Week 16

  3. Number of Participants With Peak Eosinophil Count Less Than (<)15/High-Powered Field (HPF) or Less Than or Equal to (<=)1/High-Powered Field (HPF) at the Final Treatment Period Evaluation (Week 16)

    Participant was considered as responder at Week 16 if he/she had peak eosinophil count of \<15/HPF or \<=1/HPF across all esophagus levels. Number of participants with peak eosinophil count \< 15/HPF or \<=1/HPF after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Week 16

  4. Change From Baseline in the Peak Eosinophil Count at the Final Treatment Period Evaluation (Week 16)

    Change from baseline in the peak eosinophil count after 12 weeks of double blind treatment at week 16 for each available esophageal level (proximal, mid, distal, maximum) were reported.

    Time frame: Baseline, Week 16

  5. Change From Baseline in the Histopathologic Epithelial Features Combined Total Score Ratio (TSR) at the Final Treatment Period Evaluation (Week 16)

    Change from baseline in histopathologic epithelial features combined total score of grade and stage ratio after 12 weeks of double blind treatment at Week 16 were reported by measuring eight histopathologic epithelial features: basal layer hyperplasia, eosinophil density, eosinophil micro-abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis were scored on a 4-point scale (0=normal, 3=worst) for both the severity of the abnormality (grade) and the amount of tissue affected by the abnormality (stage). Thus each of the 3 levels had a minimum score of 0 and maximum possible score of 24, and a possible total grade or stage score of 72 for a maximum combined score of 144. Combined total score ratio (TSR) =(proximal TSR + mid TSR + distal TSR)/N, where N is the number of non missing sections for TSR. A negative change from baseline indicates that epithelial inflammation decreased.

    Time frame: Baseline, Week 16

  6. Number of Participants With Dysphagia Symptom Response (Binary Response) at the Final Treatment Period Evaluation (Week 16)

    Dysphagia symptom response (binary response \[i.e, responders versus. non-responders\]) was defined as a \>=50% reduction in the DSQ combined score (questions 2+3), from baseline to the final treatment period evaluation (Week 16). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Number of participants with binary response after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Week 16

  7. Number of Participants With Overall Binary Response I at the Final Treatment Period Evaluation (Week 16)

    Overall binary response I was defined as a reduction in the DSQ score of \>=30% from baseline to the final treatment period (week 16) evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 30% reduction in DSQ combined score between baseline and Week 16 and has peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response I after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Week 16

  8. Number of Participants With Overall Binary Response II at the Final Treatment Period Evaluation (Week 16)

    Overall binary response II was defined as a reduction in the DSQ score of \>=50% from baseline to the final treatment period evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 50% reduction in DSQ combined score between baseline and Week 16 and had peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response II after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Week 16

  9. Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16)

    DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ + pain score was calculated by summing the scores of responses to questions 2, 3, and 4 by using following formula: DSQ + pain score= (\[sum of points from questions 2+3+4 in the daily DSQ\] ×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2, 0 - 4 for question 3 and 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ + pain score was 0 - 140, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Week 16

  10. Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16)

    DSQ pain score was calculated by summing the scores of responses to Question 4 (extent to which the participant experienced pain while swallowing) only, by using the following formula: DSQ pain score= \[(sum of points from question 4 in the daily DSQ)×14\]/ Number of diaries reported with non-missing data. Scale range was 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ pain score was 0 - 56, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ pain score (question 4) after 12 weeks of double blind treatment at Week 16 were reported.

    Time frame: Baseline, Week 16

  11. Number of Participants With Treatment-Emergent Adverse Events (AE)

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that start or deteriorate on or after the first dose of double-blind IP (Week 44) and through the safety follow-up contact, or 31 days after the last dose of IP for participants who did not have a safety follow-up contact. Number of participants with TEAE's were reported.

    Time frame: From start of study drug administration up to follow-up (Week 20)

  12. Area Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses

    Area under the curve for the defined interval between doses (12 hours), calculated using the linear-up/log-down trapezoidal rule.The AUCtau of plasma budesonide was reported. Hours times pico grams per milliliter was abbreviated as h.pg/mL.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  13. Maximum Observed Concentration (Cmax) of Budesonide in Plasma

    The Cmax of budesonide in plasma was reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  14. Time to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma

    Tmax of budesonide in plasma was reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  15. Terminal Rate Constant (Lambda Z) of Budesonide in Plasma

    Lambda Z of budesonide in plasma was reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  16. Terminal Half-Life (t1/2) of Budesonide in Plasma

    t1/2 of budesonide in plasma was reported

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  17. Apparent Oral Clearance (CL/F) of Budesonide in Plasma

    CL/F of budesonide in plasma was reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

  18. Apparent Volume of Distribution (Vz/F) of Budesonide in Plasma

    Vz/F of budesonide in plasma was reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16

07

Results

Posted Mar 16, 2020

Participant flow

This study was conducted at 72 sites in North America from 07 December 2015 (first participant enrolled) to 15 February 2019 (last participant completed).

Participant flow — Overall Study
MilestonePlaceboOral Budesonide Suspension (OBS)
Started105213
Completed94202
Not completed1111
Withdrew: Adverse event31
Withdrew: Non-compliance with study drug01
Withdrew: Withdrawal by subject88
Withdrew: Physician decision01

Outcome measures

PrimaryNumber of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16)

Histologic response was defined as a peak eosinophil count of less than or equal to (\<=) 6/ high-powered field (HPF) across all available esophageal levels at final treatment period evaluation (Week 16). Histologic response after 12 weeks of double blind treatment at Week 16 was reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Histology Response - Yes1113
Histology Response - No104100
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in proportion of responders: 0.52 · 95% CI 0.433 to 0.591
PrimaryNumber of Participants With Dysphagia Symptom Response at the Final Treatment Period Evaluation (Week 16)

Dysphagia symptom response was defined as greater than or equal to (\>=) 30 percent (%) reduction in the Dysphagia Symptom Questionnaire (DSQ) combined score (questions 2+3). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Dysphagia symptom response after 12 weeks of double blind treatment at Week 16 was reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Dysphagia Symptom Response at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Dysphagia symptom response: Yes41112
Dysphagia symptom response: No64101
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Cochran-Mantel-Haenszel · p = 0.024 · Difference in proportion of responders: 0.13 · 95% CI 0.016 to 0.243
SecondaryChange From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16)

DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ combined score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2 and 0 - 4 for question 3, with higher values representing a worse outcome. Scale range for DSQ combined score was 0 - 84, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ after 12 weeks of double blind treatment at Week 16 was reported.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on scale
Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16)
Score on scalePlaceboOral Budesonide Suspension (OBS)
Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Combined Score at the Final Treatment Period Evaluation (Week 16)-9.07 ± 1.519-12.99 ± 1.202
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = 0.015 · Difference in least square mean: -3.92 · 95% CI -7.073 to -0.774
SecondaryChange From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16)

Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 categories: 1) exudates or plaques (grade 0-2); 2) fixed esophageal rings (grade 0-3); 3) edema (grade 0-2); 4) furrows (grade 0-2); and 5) strictures (grade 0-1). An endoscopy score for each category was calculated and summed for each anatomic location (proximal and distal). The minimum and maximum endoscopy score was 0 and 10 points respectively for each location (proximal and distal) and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points respectively). The higher score indicated worse appearance. A negative change from baseline indicates that appearance improved. Endoscopic findings after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on scale
Change From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16)
score on scalePlaceboOral Budesonide Suspension (OBS)
Change From Baseline in Total Endoscopy Score at the Final Treatment Period Evaluation (Week 16)-2.2 ± 0.38-4.0 ± 0.30
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -1.8 · 95% CI -2.6 to -1.1
SecondaryNumber of Participants With Peak Eosinophil Count Less Than (<)15/High-Powered Field (HPF) or Less Than or Equal to (<=)1/High-Powered Field (HPF) at the Final Treatment Period Evaluation (Week 16)

Participant was considered as responder at Week 16 if he/she had peak eosinophil count of \<15/HPF or \<=1/HPF across all esophagus levels. Number of participants with peak eosinophil count \< 15/HPF or \<=1/HPF after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Peak Eosinophil Count Less Than (<)15/High-Powered Field (HPF) or Less Than or Equal to (<=)1/High-Powered Field (HPF) at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Peak Eosinophil Count (<15/HPF): Responders1132
Peak Eosinophil Count (<15/HPF): Non-responders10481
Peak Eosinophil Count (<=1/HPF): Responders069
Peak Eosinophil Count (<=1/HPF): Non-responders105144
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Regression, Logistic · p = <0.001 · Odds ratio (or): 169.74 · 95% CI 23.235 to 1239.979
  • Placebo vs Oral Budesonide Suspension (OBS) · Firth logistic regression · p = 0.001 · Odds ratio (or): 100.69 · 95% CI 6.294 to 1610.749
SecondaryChange From Baseline in the Peak Eosinophil Count at the Final Treatment Period Evaluation (Week 16)

Change from baseline in the peak eosinophil count after 12 weeks of double blind treatment at week 16 for each available esophageal level (proximal, mid, distal, maximum) were reported.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · eosinophil count
Change From Baseline in the Peak Eosinophil Count at the Final Treatment Period Evaluation (Week 16)
eosinophil countPlaceboOral Budesonide Suspension (OBS)
Proximal: Week 16-5.5 ± 3.19-34.0 ± 2.52
Mid: week 16-12.9 ± 3.74-43.3 ± 3.01
Distal: Week 16-4.9 ± 3.66-38.0 ± 2.88
Maximum: Week 16-7.6 ± 4.27-55.2 ± 3.37
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -28.4 · 95% CI -35.0 to -21.8
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -30.4 · 95% CI -38.1 to -22.7
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -33.1 · 95% CI -40.7 to -25.5
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in ls mean: -47.6 · 95% CI -56.4 to -38.8
SecondaryChange From Baseline in the Histopathologic Epithelial Features Combined Total Score Ratio (TSR) at the Final Treatment Period Evaluation (Week 16)

Change from baseline in histopathologic epithelial features combined total score of grade and stage ratio after 12 weeks of double blind treatment at Week 16 were reported by measuring eight histopathologic epithelial features: basal layer hyperplasia, eosinophil density, eosinophil micro-abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis were scored on a 4-point scale (0=normal, 3=worst) for both the severity of the abnormality (grade) and the amount of tissue affected by the abnormality (stage). Thus each of the 3 levels had a minimum score of 0 and maximum possible score of 24, and a possible total grade or stage score of 72 for a maximum combined score of 144. Combined total score ratio (TSR) =(proximal TSR + mid TSR + distal TSR)/N, where N is the number of non missing sections for TSR. A negative change from baseline indicates that epithelial inflammation decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on scale
Change From Baseline in the Histopathologic Epithelial Features Combined Total Score Ratio (TSR) at the Final Treatment Period Evaluation (Week 16)
score on scalePlaceboOral Budesonide Suspension (OBS)
Grade - Combined TSR: Week 16-0.03 ± 0.016-0.22 ± 0.013
Stage - Combined TSR: Week 16-0.0 ± 0.02-0.2 ± 0.01
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -0.19 · 95% CI -0.22 to -0.16
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = <0.001 · Difference in least square mean: -0.2 · 95% CI -0.2 to -0.2
SecondaryNumber of Participants With Dysphagia Symptom Response (Binary Response) at the Final Treatment Period Evaluation (Week 16)

Dysphagia symptom response (binary response \[i.e, responders versus. non-responders\]) was defined as a \>=50% reduction in the DSQ combined score (questions 2+3), from baseline to the final treatment period evaluation (Week 16). DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score= (\[sum of points from questions 2+3 in the daily DSQ\]×14)/ Number of diaries reported with non-missing data. Number of participants with binary response after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Dysphagia Symptom Response (Binary Response) at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Responders3588
Non Responders70125
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Regression, Logistic · p = 0.164 · Odds ratio (or): 1.42 · 95% CI 0.866 to 2.333
SecondaryNumber of Participants With Overall Binary Response I at the Final Treatment Period Evaluation (Week 16)

Overall binary response I was defined as a reduction in the DSQ score of \>=30% from baseline to the final treatment period (week 16) evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 30% reduction in DSQ combined score between baseline and Week 16 and has peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response I after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Overall Binary Response I at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Overall Binary Response I: Responders064
Overall Binary Response I: Non Responders105149
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Firth logistic regression · p = 0.001 · Odds ratio (or): 91.86 · 95% CI 5.687 to 1483.680
SecondaryNumber of Participants With Overall Binary Response II at the Final Treatment Period Evaluation (Week 16)

Overall binary response II was defined as a reduction in the DSQ score of \>=50% from baseline to the final treatment period evaluation and a peak eosinophil count of \<=6/HPF across all esophageal levels at the final treatment period evaluation. Participant was considered as responder at Week 16 if he/she achieved a minimum of 50% reduction in DSQ combined score between baseline and Week 16 and had peak eosinophil count of \<=6/HPF across all esophagus levels. Number of participants with overall binary response II after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Overall Binary Response II at the Final Treatment Period Evaluation (Week 16)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Overall binary response II: Responders048
Overall binary response II: Non-Responders105165
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · Firth logistic regression · p = 0.004 · Odds ratio (or): 61.68 · 95% CI 3.836 to 991.858
SecondaryChange From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16)

DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ + pain score was calculated by summing the scores of responses to questions 2, 3, and 4 by using following formula: DSQ + pain score= (\[sum of points from questions 2+3+4 in the daily DSQ\] ×14)/ Number of diaries reported with non-missing data. Scale range was 0 - 2 for question 2, 0 - 4 for question 3 and 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ + pain score was 0 - 140, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on scale
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16)
Score on scalePlaceboOral Budesonide Suspension (OBS)
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) + Pain Score (Questions 2 +3+4) at the Final Treatment Period Evaluation (Week 16)-12.24 ± 2.097-18.65 ± 1.660
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = 0.004 · Difference in least square mean: -6.41 · 95% CI -10.757 to -2.063
SecondaryChange From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16)

DSQ pain score was calculated by summing the scores of responses to Question 4 (extent to which the participant experienced pain while swallowing) only, by using the following formula: DSQ pain score= \[(sum of points from question 4 in the daily DSQ)×14\]/ Number of diaries reported with non-missing data. Scale range was 0 - 4 for question 4, with higher values representing a worse outcome. Scale range for DSQ pain score was 0 - 56, with higher values representing a worse outcome. A negative change from baseline indicates that symptoms decreased. Change from baseline in DSQ pain score (question 4) after 12 weeks of double blind treatment at Week 16 were reported.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on scale
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16)
score on scalePlaceboOral Budesonide Suspension (OBS)
Change From Baseline in the Dysphagia Symptom Questionnaire (DSQ) Pain Score (Question 4) at the Final Treatment Period Evaluation (Week 16)-3.01 ± 0.751-5.47 ± 0.595
Statistical analysis
  • Placebo vs Oral Budesonide Suspension (OBS) · ANCOVA · p = 0.002 · Difference in least square mean: -2.46 · 95% CI -4.018 to -0.909
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AE)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that start or deteriorate on or after the first dose of double-blind IP (Week 44) and through the safety follow-up contact, or 31 days after the last dose of IP for participants who did not have a safety follow-up contact. Number of participants with TEAE's were reported.

Time frame:
From start of study drug administration up to follow-up (Week 20)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AE)
ParticipantsPlaceboOral Budesonide Suspension (OBS)
Number of Participants With Treatment-Emergent Adverse Events (AE)64130
SecondaryArea Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses

Area under the curve for the defined interval between doses (12 hours), calculated using the linear-up/log-down trapezoidal rule.The AUCtau of plasma budesonide was reported. Hours times pico grams per milliliter was abbreviated as h.pg/mL.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · h.pg/mL
Area Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses
h.pg/mLOral Budesonide Suspension (OBS)
Area Under the Plasma Concentration-Time Curve (AUCtau) Between the Defined Interval of Budesonide Doses5071 ± 58.1
SecondaryMaximum Observed Concentration (Cmax) of Budesonide in Plasma

The Cmax of budesonide in plasma was reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · Picograms per milliliter (pg/mL)
Maximum Observed Concentration (Cmax) of Budesonide in Plasma
Picograms per milliliter (pg/mL)Oral Budesonide Suspension (OBS)
Maximum Observed Concentration (Cmax) of Budesonide in Plasma914.8 ± 59.2
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma

Tmax of budesonide in plasma was reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Median · hour
Time to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma
hourOral Budesonide Suspension (OBS)
Time to Maximum Observed Plasma Concentration (Tmax) of Budesonide in Plasma2 (0.50 to 4)
SecondaryTerminal Rate Constant (Lambda Z) of Budesonide in Plasma

Lambda Z of budesonide in plasma was reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · per hour
Terminal Rate Constant (Lambda Z) of Budesonide in Plasma
per hourOral Budesonide Suspension (OBS)
Terminal Rate Constant (Lambda Z) of Budesonide in Plasma0.2103 ± 25.2
SecondaryTerminal Half-Life (t1/2) of Budesonide in Plasma

t1/2 of budesonide in plasma was reported

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · hour
Terminal Half-Life (t1/2) of Budesonide in Plasma
hourOral Budesonide Suspension (OBS)
Terminal Half-Life (t1/2) of Budesonide in Plasma3.296 ± 25.2
SecondaryApparent Oral Clearance (CL/F) of Budesonide in Plasma

CL/F of budesonide in plasma was reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Oral Clearance (CL/F) of Budesonide in Plasma
Liter per hour (L/h)Oral Budesonide Suspension (OBS)
Apparent Oral Clearance (CL/F) of Budesonide in Plasma394.4 ± 58.1
SecondaryApparent Volume of Distribution (Vz/F) of Budesonide in Plasma

Vz/F of budesonide in plasma was reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Week 8, 12 and 16
Reported as:
Geometric mean · Liter (L)
Apparent Volume of Distribution (Vz/F) of Budesonide in Plasma
Liter (L)Oral Budesonide Suspension (OBS)
Apparent Volume of Distribution (Vz/F) of Budesonide in Plasma1886 ± 51.4

Adverse events

Collected over From start of study drug administration up to follow-up (Week 20). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/105 (0%)1/105 (1%)28/105 (26.7%)
Oral Budesonide Suspension (OBS)0/213 (0%)2/213 (0.9%)63/213 (29.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboOral Budesonide Suspension (OBS)
Ovarian cystReproductive system and breast disorders1/1050/213
Localised intraabdominal fluid collectionGastrointestinal disorders0/1051/213
GastroenteritisInfections and infestations0/1051/213
SepsisInfections and infestations0/1051/213
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboOral Budesonide Suspension (OBS)
NasopharyngitisInfections and infestations4/10511/213
DiarrhoeaGastrointestinal disorders5/1052/213
SinusitisInfections and infestations3/1059/213
VomitingGastrointestinal disorders4/1054/213
Mood swingsPsychiatric disorders4/1053/213
Oesophageal candidiasisInfections and infestations2/1058/213
Oral candidiasisInfections and infestations0/1058/213
HeadacheNervous system disorders1/1057/213
NauseaGastrointestinal disorders3/1056/213
Upper respiratory tract infectionInfections and infestations3/1054/213

Baseline characteristics

Full analysis set (FAS) included all randomized participants who received at least one dose of a double-blind investigational product (IP).

Age, Continuous
Age, Continuous(Years)PlaceboOral Budesonide Suspension (OBS)Total
Mean33.9 ± 12.1333.8 ± 11.8933.9 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOral Budesonide Suspension (OBS)Total
Female4384127
Male62129191
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOral Budesonide Suspension (OBS)Total
Hispanic or Latino2810
Not Hispanic or Latino100204304
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOral Budesonide Suspension (OBS)Total
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American055
White101200301
More than one race000
Unknown or Not Reported3710
08

Study locations

77 sites
  • Children's Hospital
    Birmingham, Alabama 35233, United States
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Del Sol Research Management
    Tucson, Arizona 85710, United States
  • Adobe Clinical Research LLC
    Tucson, Arizona 85712, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • GW Research, Inc.
    Chula Vista, California 91910, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Colorado Children's Hospital
    Aurora, Colorado 80045, United States
  • Asthma and Allergy Associates PC
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Pediatric Gastroenterology
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Clinical Research LLC
    Wheat Ridge, Colorado 80033, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Connecticut GI, PC - Research Division
    Farmington, Connecticut 06032, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Nature Coast Clinical Research LLC
    Inverness, Florida 34452, United States
  • Borland Groover Clinic
    Jacksonville, Florida 32256, United States
  • Arnold Palmer Hospital For Children
    Orlando, Florida 32806, United States
  • Accord Clinical Research LLC
    Port Orange, Florida 32129, United States
  • Children's Center for Digestive Health Care
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • Ann and Robert H Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Center for Children's Digestive Health
    Park Ridge, Illinois 60068, United States
  • University of Illinois College of Medicine at Peoria Pediatric Subspecialty Clinic
    Peoria, Illinois 61603, United States
  • OSF St Francis Medical Center
    Peoria, Illinois 61637, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Gastroenterology of Southern Indiana
    New Albany, Indiana 47150, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Gastroenterology Associates LLC
    Baton Rouge, Louisiana 70809, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Louisiana Research Center LLC
    Shreveport, Louisiana 71105, United States
  • Clinical Trials of America LA LLC - PPDS
    West Monroe, Louisiana 71291, United States
  • Tufts Medical Center
    Boston, Massachusetts 00211, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • West Michigan Clinical Research
    Wyoming, Michigan 49519, United States
  • University of Minnesota
    Minneapolis, Minnesota 55454, United States
  • Minnesota Gastroenterology PA
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59718, United States
  • South Jersey Gastroenterology
    Marlton, New Jersey 08053, United States
  • Long Island Gastrointestinal Research Group LLP
    Great Neck, New York 11023, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Asheville Gastroenterology Associates PA
    Asheville, North Carolina 28801, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Clinical Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Clinical Trials of America-NC, LLC - PPDS
    Mount Airy, North Carolina 27030, United States
  • Consultants For Clinical Research Inc
    Cincinnati, Ohio 45219, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Gastrointestinal and Liver Diseases Consultants PC
    Dayton, Ohio 45415, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Greenville Hospital System
    Greenville, South Carolina 29615, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • San Antonio Military Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Endoscopy and Research Center
    Houston, Texas 77079, United States
  • Digestive Health Center
    Pasadena, Texas 77505, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Advanced Research Institute
    Ogden, Utah 84092, United States
  • Primary Children's Hospital, University of Utah
    Salt Lake City, Utah 84113, United States
  • Advanced Research Institute
    Sandy, Utah 84092, United States
  • Emeritas Research Group
    Lansdowne Town Center, Virginia 20176, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • Carilion Clinic
    Roanoke, Virginia 24013, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Dellon ES, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Goodwin B, Eisner JD, Lan L, Desai NK, Williams J, Hirano I; ORBIT2/SHP621-302 Investigators. Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1488-1498.e11. doi: 10.1016/j.cgh.2021.06.020. Epub 2021 Jun 26. PubMed 34182150 ↗
  • Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Desai NK, Lan L, Williams J, Dellon ES; ORBIT1/SHP621-301 Investigators. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19. Erratum In: Clin Gastroenterol Hepatol. 2022 Oct;20(10):2418. doi: 10.1016/j.cgh.2022.07.003. PubMed 33887475 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jan 2019, 37 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
Nov 16, 2015
StartActual
Dec 7, 2015
Primary completionActual
Jan 24, 2019
CompletionActual
Feb 15, 2019
Results first posted
Mar 16, 2020
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02605837
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
Dec 7, 2015
Primary completion
Jan 24, 2019
Completion
Feb 15, 2019
Results posted
Mar 16, 2020
Last update
Feb 19, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion